News

Technology for protein fingerprints may aid with early diagnosis

Inoviq’s Neuro-Net technology can aid in diagnosing Parkinson’s disease at early stages, with it having effectively isolated and identified brain-released exosomes, small vesicles whose information can act as disease fingerprints, in patients’ blood, the company announced. Measuring known biomarkers of the neurodegenerative disease using this technology enriched their…

In Parkinson’s, adaptive DBS better than standard DBS procedure

Adaptive deep brain stimulation (DBS) outperformed traditional DBS in alleviating motor symptoms and enhancing the quality of life for people with Parkinson’s disease, a pilot study shows. In adaptive DBS, nerve signals associated with motor fluctuations are detected in real time and stimulation is automatically adjusted to ease…

Cycling better than electrical muscle stimulation for cognition: Study

Cycling was more effective than electrical muscle stimulation at improving cognitive function, according to a small study. The results have implications for neurodegenerative diseases like Parkinson’s in which both movement and cognition can be affected. “Our results suggest that the relationship between exercise and brain activity is crucial for faster…

BBSome complex guides dopamine transport; may impact Parkinson’s

A complex of proteins involved in cellular trafficking, called the BBSome, plays a role in regulating the transport of dopamine, the nerve cell signaling molecule that’s deficient in Parkinson’s disease, a study reveals. “Given the significant medical impact of altered dopamine signaling in multiple neurobehavioral disorders, further studies of…

Phase 2 trial of VG081821 to ease motor symptoms fully enrolled

Enrollment is complete in a Phase 2 trial of VG081821, an investigational therapy to treat early to mid-stage Parkinson’s disease, the therapy’s developer, Vimgreen, announced. A total of 150 patients have been randomized to receive a low or high dose of VG081821 or a placebo for 12 weeks, or…